�B��
�B��


World Health Organization (WHO) �ɂ��x���̑g�D���ނ́C1967�N�ɑ�1�ł����s���ꂽ�̂��C��2�Łi1981�N�j�C��3�Łi1999�N�j�Ɖ�������C��`�q�ُ�Ɋւ���L�ڂ��܂�2004�N�ł����s���ꂽ[1]�D���̌�C�x���Ɋւ���V�����m�����~�ς��C2011�N�ɁC���۔x���w��E�A�����J���������w��E���[���b�p�ċz��w��狤���Ŕx�B���̐V���ށiIASLC/ATS/ERS�V���ށj���񎦂��ꂽ[2]�D�{�e�ł́C�x�B���̐V���ނ𒆐S�ɉ��������D

�B��

��`�F�B�o�`���A�S�t�Y���A�܂����x�E���זE�}�[�J�[(TTF-1, Napsin A)���z��������������琫���

�O�Z�����a��

1999�N�����2004�N��WHO���ނł́C�B���̈��^�Ƃ��ĐZ���̂Ȃ��B����brochioloalveolar carcinoma (BAC)�ƌĂсC�܂���ᇍזE�������̔x�E�ǂɉ����đ��B����p�^�[����BAC�p�^�[���ĂԂ悤�ɁCBAC��2��ނ̈Ӗ��ŗp���Ă���D�܂��C�K�������\�オ�ǍD�ł͂Ȃ��S�t�Y������BAC�����݂���D1999�N�����2004�N��WHO���ނł́C�O�Z�����a�ςƂ��āC�ٌ`���Ə������C�ٌ^�B��l�ߌ`���C�т܂񐫓������x�_�o������זE�ߌ`���������Ă��邪�CBAC�͐Z���̂Ȃ��B���ł���̂ɑO�Z�����a�ςɊ܂܂�Ă��Ȃ��D���̂悤�Ȗ������������邽�߂ɁCIASLC/ATS/ERS�V���ނł́CBAC�Ƃ����p��͗p�����C������lepidic�p�^�[����p���C�B���̑O�Z�����a�ςƂ��ď����B�����������D

lepidic�p�^�[���Ƃ́H

�ٌ^�B��l�ߌ`���@Atypical adenomatous hyperplasia �iAAH�j

�ٌ^�B��l�ߌ`���̑傫���́C�ʏ�5mm�ȉ��ł���C�������邱�Ƃ�����D�y�x���璆���x�ٌ̈^��������II�^�x�E���זE�i���邢�̓N�����זE�j���x�E�ǁi���邢�͌ċz�׋C�ǎx�j�ɉ����đ������邪�C�זE�ƍזE�̊ԂɌ��Ԃ��݂���D�j�������̂��݂���D�ٌ^���������זE���x�������ꍇ�́CAAH�Ə����B��Adenocarcinoma in situ (AIS)�̊ӕʂ͓���D

�����B���@Adenocarcinoma in situ (AIS)

�]����BAC�ł���D�Ǘ����ŁC��ᇌa��3cm�ȉ��ŁC�����̔x�E�ǂɉ����Ď�ᇍזE�����B���ilepidic�p�^�[���j�C�Ԏ��C���ǁC�����ւ̐Z����F�߂Ȃ����̂������D�����^�C���������^��x�E�o���̎�ᇍזE�݂͂��Ȃ��D�唼���S�t��Y�����ŁCII�^�x�E��炠�邢��Clara�זE����Ȃ�D�܂�ɁC�S�t�Y���������B�������݂���D����́C���~����זE����Ȃ�C�j�͊�ꕔ�ɕ��сC�זE���ɖL�x�ȔS�t�����Ă���D

��ᇂ�lepidic�p�^�[���݂̂���Ȃ��Ă��C��ᇌa��3cm�𒴂���ꍇ�́Clepidic predominant adenocarcinoma�Ɛf�f���C�����B�����^����ƃR�����g������D

�����Z�����B���@Minimally invasive adenocarcinoma (MIA)

��ᇌa��3cm�ȉ��ŁClepidic�p�^�[�����D�ʂŁC�Z���a��0.5cm�ȉ��̑B��������Z�����B���Ƃ���D

�Z���Ƃ́H

�Z�������������‘��݂���ꍇ�́C�ő�̐Z�����̌a�����̎�ᇂ̐Z���a�Ƃ���D
�Z���̌v��������ȏꍇ�́C��ᇌa�ɐZ�������̑��a�ɑ΂��銄���������āC�Z���a�Ƃ���D

Lepidic�p�^�[�����D�ʂł��C��ᇌa��3cm�𒴂���ꍇ��C�Z���a��0.5cm�𒴂���ꍇ�́Clepidic predominant adenocarcinoma�Ɛf�f����D

�Z�����B���@Invasive adenocarcinoma



IASLC/ATS/ERS�V���ނł́C�����^�B��(adenocarcinoma mixed subtype)��p�����C����ɑ���������̂Ƃ��āC�Z�����B����p����D��ᇓ��ɑ��݂���p�^�[���ilepidic�C�B�[�^�C�����^�C���������^�C�S�t�Y���[���^�j�̐�߂銄����5%�����݂ŋL�^����D�Z�����B���́C�D�ʂȑg�D�p�^�[���ɂ��lepidic adenocarcinoma�C�B�[�^(acinar adenocarcinom)�C�����^(papillary adenocarcinoma)�C���������^(micropapillary adenocarcinoma)�C�[���^(solid adenocarcinoma)�Ɉ����ނ���D�]�������^�B���ɕ��ނ���Ă����S�t��Y����BAC�D�ʂ̑B���́Clepidic predominant adenocarcinoma (LPA)�ɕ��ނ���D �����B���ɂ����Ĕ��������^�͗\�オ�s�ǂł���D

����^

����^�Ƃ��āC�Z�����S�t�B���i�]���̔S�t�Y����BAC�jinvasive mucinous adenocarcinoma�C�R���C�h�B��colloid adenocarcinoma�C�َ��^�B��fetal adenocarcinoma�i��ٌ^�x�C���ٌ^�x�j�C���^�B��enteric adenocarcinoma�������Ă���D

�Z�����S�t�B���@Invasive mucinous adenocarcinoma

�]���̔S�t�Y����(mucinous) BAC�́C�Տ��I�ɂ����ː��摜�I�ɂ��]���̔S�t��Y����(nonmucinous) BAC�Ƃ͈قȂ�D���������āC���̎�ᇂ͈ȑO��nonmucinous BAC�Ƃ͕ʂɕ��ނ��Clepidic growth�ƐZ���a�ɂ��S�t�Y���������B��mucinous AIS, �S�t�Y���������Z�����B��mucinous MIA, �Z�����S�t�B��invasive mucinous adenocarcinoma�ɕ��ނ���D

�S�t�Y���������B���@Mucinous AIS

Mucinous AIS�́C��ᇌa��3cm�ȉ��ŁC�Z�����Ȃ��D

�S�t�Y���������Z�����B���@Mucinous MIA

Mucinous MIA�͎�ᇌa��3cm�ȉ��ŁC�Z���a��0.5cm�ȉ��ł���D

�Z�����S�t�B���@Invasive mucinous adenocarcinoma

�Z�����S�t�B���͑������ł���C���̔x�t�C�Α��x�ɂ��a�ς�F�߂邱�Ƃ������D���͂̔x�E�Ɏ�ᇂ��U�z��ɍL���邽�ߎ�ᇂ̋��E�͖��Ăł͂Ȃ��D��ᇍזE�͔t�זE�l���邢�͉~����ł���D��ᇍזE�ٌ̈^���͒ʏ�C�y�x�ł���D�Z�����S�t�B����lepidic�p�^�[���C�B�[�^�C�����^�C���������^�C�[���^�̊e�p�^�[���������D�S�t���Y�����Ă��C�t�זE�l���邢�͍��~����ł͂Ȃ��ꍇ�́C�Z�����S�t�B���Ƃ͂��Ȃ��D

�S�t�Y�����E��Y���������^�B���@Mixed invasive mucinous and non-mucinous adenocarcinoma

�S�t�Y�����B���ƔS�t��Y�����B�����������邱�Ƃ�����C���ꂼ�ꂪ10%�ȏ���߂�D

�R���C�h�B���@Colloid adenocarcinoma



�R���C�h�B���́C�זE�O�ɑ��ʂ̔S�t��F�߁C�x�E�o���g�����C�x�E�ǂ��j�󂳂�Ă���D��ᇍזE�͔S�t�̒��ɕ��V���Ă���D1999�N�����2004�N��WHO���ނɋL�ڂ�����S�t�X�E�B��mucinous cystadenocarcinoma�͋ɂ߂Ă܂�ł���C�R���C�h�B���Ɠ����X�y�N�g�����ɂ���ƍl�����邽�߁C�R���C�h�B���ɕ��ނ���D

�َ��^�B���@Fetal adenocarcinoma

�َ��^�B���́C�O���R�[�Q���ɕx�ޖ����эזE���B�o���`�����C�َ��̔x�ɗގ����Ă���D�j��C�j����E��F�߂�D��ٌ^�x�َ��^�B���́Cmorule�Ƃ�΂�鋅��W���F�߁C�j��optically clear nucleus�Ƃ�΂�邷��K���X��ω��𔺂��D���̊j�̓r�I�`���ɕx��[3]�D���J�e�j����`�q�ُ̈�ɂ�蔭�����C�Ɖu���F�Ń��J�e�j���́C��ᇍזE�̊j����эזE�����z���ɂȂ�[4, 5]�D���ٌ^�x�َ��^�B���̓��J�e�j����`�q�ُ̈�͔F�߂��C�Ɖu���F�Ń��J�e�j���͎�ᇍזE�̍זE�����z���ɂȂ�D�O�҂͌�҂�����N�҂ɔ������C�\�オ�ǍD�ł���D

���^�B���@Enteric adenocarcinoma

���^�B���͒����ւ̕����𔺂��זE����ᇂ�50%�ȏ���߂���̂������D�咰���̔x�]�ڂƂ͈قȂ�C�g�D�������ʂŁC�ʏ�̔x�B���̑g�D�����݂���D��ᇍזE�͍��~����ŁC�j�̋U�d�w����F�߁C�B�o�`���C�����󑝐B�������C⿏�z����������Ƃ�����D�Ɖu���F�͒����ւ̕���������CDX-2, CK20, MUC2�Ȃǂ��z���ɂȂ�D�񔼐��̏Ǘ�́CCK7, TTF-1���z���ɂȂ�̂ŁC�x�������咰���̓]�ڂ��̊ӕʂɖ𗧂D

��זE��signet ring adenocarcinoma�C�W���זE�B����clear cell adenocarcinoma�͑��̑g�D�p�^�[���ɍ������Ă݂���זE�w�I�ω��ł���D����炪���݂���ꍇ�́C���̑g�D�p�^�[���͈̔͂��L�^����ׂ��ł��邪�C�[���^�Ƃ̊ԂɗՏ��I�ȍ��ق��݂��Ȃ����߁CIASLC/ATS/ERS�V���ނ̑g�D���ނ���͍폜���ꂽ�D�������CALK��`�q�̍č\�������݂���x���ɂ͈�זE�����܂ޕp�x������[6]�CALK��`�q�̍č\���𔺂��B����ALK tyrosine kinase inhibitor (TKI)�ł���crizotinib���t�����邱�Ƃ��񍐂���Ă���[7, 8]�D

��זE���̑��������B���@solid adenocarcinoma with signet ring cell feature


���}�F��זE���̑����������זE���[�����ɑ��B�����Ă���D
�E�}�FFISH�ɂ��ALK��`�q���]�����������Ă��邱�Ƃ��킩��D

Spread through air spaces (STAS)



��ᇂ̕Ӊ�������͂̔x�E�o���ɔ���������̃N���X�^�[�C�[�����E���C�Ǘ�����ᇍזE��F�߂邱�Ƃ�����D�a���h�̏��^�̑B���ɑ΂��ĕ����؏��������ꍇ�ɁC���̏���������ƍĔ��̉”\���������DSTAS�͎�ᇂ̐i�W�l���ł���C�B���̃p�^�[���Ƃ��Ă��̐�߂銄���𑪒肵�Ȃ��D�܂��C��ᇌa�ɂ�����Ȃ��D

�B���̑g�D���^�ƈ�`�q�ُ�

�B���̈�`�q�ُ�Ƒg�D�^�ɂ͂�����x�֌W������DKRAS�ˑR�ψق͐Z�����S�t�B���ŕp�x������[2, 14]�C�܂��C�����^�C�[���^�C����������ᕪ���̑B���ŕp�x������[14-17]�DEGFR�ˑR�ψق͔S�t��Y����lepidic�p�^�[���C��[���^�ŕp�x������[2, 16, 17]�C���������獂�����̑B���ŕp�x������[14]�DALK��`�q�̍č\���͈�זE�����܂ޔx�B���̕p�x������[6]�C�g�D���^�́C�����^�C�S�t�B���ŕp�x������[16]�DEGFR��`�q, ALK��`�q�ُ̈�������x���̊j�ٌ^�x�́CKRAS��`�q�ُ̈�������x���̊j�ٌ^�x�����Ⴂ[16]�D


���p����
1) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. In: Travis W, Brambilla E, Muller-Hermelink H, Harris C, editors. Lyon: IARC Press, 2004:10-124.
2) Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
3) Nakatani Y, Kitamura H, Inayama Y, Ogawa N. Pulmonary endodermal tumor resembling fetal lung. The optically clear nucleus is rich in biotin. Am J Surg Pathol 1994;18:637-642.
4) Nakatani Y, Masudo K, Miyagi Y, Inayama Y, Kawano N, Tanaka Y, et al. Aberrant nuclear localization and gene mutation of beta-catenin in low-grade adenocarcinoma of fetal lung type: up-regulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules. Mod Pathol 2002;15:617-624.
5) Sekine S, Shibata T, Matsuno Y, Maeshima A, Ishii G, Sakamoto M, et al. Beta-catenin mutations in pulmonary blastomas: association with morule formation. J Pathol 2003;200:214-221.
6) Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-5223.
7) Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
8) Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-1012.
9) Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011;24:653-664.
10) Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 2013;8:52-61.
11) Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012;30:1438-1446.
12) Thunnissen E, Beasley MB, Borczuk AC, Brambilla E, Chirieac LR, Dacic S, et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol 2012;25:1574-1583.
13) Warth A, Cortis J, Fink L, Fisseler-Eckhoff A, Geddert H, Hager T, et al. Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification. Virchows Arch 2012;461:185-193.
14) Dacic S, Shuai Y, Yousem S, Ohori P, Nikiforova M. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 2010;23:159-168.
15) Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992;52:2665s-2669s.
16) Motoi N, Sato S, Saito Y, Ninomiya H, Takeuchi K, Ishikawa Y. Correlation between morphologic phenotype and genotype of lung adenocarcinoma based on a new IASLC/ATS/ERS classification with nuclear grading. Mod Pathol 2013;26:461A.
17) Ang DC, Zakowski MF, Ladanyi M, Moreira AL, Rekhtman N. Characteristic morphology and immunoprofile of lung adenocarcinoma with KRAS mutations: propensity for solid growth pattern and correlation with TTF-1 expression. Mod Pathol 2010;23:396A.
18) Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012;25:405-415.
19) Pelosi G, Fabbri A, Bianchi F, Maisonneuve P, Rossi G, Barbareschi M, et al. DeltaNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol 2012;7:281-290.
20) Churg A. The fine structure of large cell undifferentiated carcinoma of the lung. Evidence for its relation to squamous cell carcinomas and adenocarcinomas. Hum Pathol 1978;9:143-156.
21) Barbareschi M, Cantaloni C, Del Vescovo V, Cavazza A, Monica V, Carella R, et al. Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. Am J Clin Pathol 2011;136:773-782.
22) Rekhtman N, Tafe LJ, Chaft JE, Wang L, Arcila ME, Colanta A, et al. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Mod Pathol 2013;26:511-522.


�{�e�Ɍf�ڂ���Ă��錰�����ʐ^�Ȃǂ́A�l�Ŏg�p�����ꍇ�́A�����R�Ƀ_�E�����[�h���Ă������������\�ł��B�������A���\�����ꍇ�⃊���N�������ꍇ�́A�o�T�𖾂炩�ɂ��Ă��������B


��32����{�Տ��זE�w���ʌ��x���E��ʌ��Տ��זE���@�w�p�W��@�u���@(2013.3.16�@���Y�a)�@����ё�13���t�x���J���t�@�����X�@�w�艉��@(2015.7.10�@����t)�@���

�������q��ȑ�w������ÃZ���^�[�a���f�f�ȁ@�A�����O